Design and validation of an immuno-PCR assay for IFN-α2b quantification in human plasma

Area of Science:

• Immunology
• Biochemistry
• Molecular Biology

Background:

• Interferon-alpha (IFN-α) is a key therapeutic target for systemic lupus erythematosus.
• Accurate quantification of low IFN-α levels in plasma is crucial for understanding disease mechanisms and treatment efficacy.

Purpose of the Study:

• To develop and validate a robust immuno-PCR (iPCR) assay for quantifying low amounts of IFN-α in human plasma.
• To assess the methodologic robustness of the iPCR assay using a Quality by Design approach.

Main Methods:

• Development of an immuno-PCR (iPCR) assay for IFN-α detection.
• Validation of the assay for accuracy, sensitivity, and selectivity.
• Application of a Plackett-Burman design to identify critical procedural steps.
• Quality by Design principles were employed for methodologic robustness analysis.

Main Results:

• The iPCR assay was validated as accurate, sensitive, selective, and versatile.
• An outstanding Limit of Detection (LOD) of 0.3 pg/ml was achieved.
• The assay demonstrated versatility for detecting and quantifying other cytokines with appropriate antibodies.

Conclusions:

• The developed iPCR assay is a reliable method for quantifying low IFN-α2b concentrations in human plasma.
• This assay can serve as a valuable clinical tool for lupus erythematosus research and diagnostics.
• The versatility of the iPCR platform allows for broader applications in cytokine analysis.